Literature DB >> 7328934

Monocyte count, monocyte chemotaxis and chemotactic factor inactivator in gastric cancer patients.

T Yamane, M Sakita, M Kasuga, B Nishioka, Y Fujita, S Majima.   

Abstract

The monocyte count in the peripheral blood, chemotactic responsiveness (MCR) and chemotactic factor inactivator (CFI) were measured in 66 patients with gastric cancer. Monocyte counts in advanced gastric cancer patients were significantly increased. MCR was significantly depressed in gastric cancer patients in the advanced stage of the disease, as compared with findings in the control groups. Sixty-seven percent of the patients with stage IV carcinoma had abnormally depressed responses. The CFIs were significantly higher in gastric cancer patients than in the control groups, and there was a positive correlation between the degree of inhibition and extent of cancer progress. These data support the hypothesis that qualitative and quantitative abnormalities of circulating monocytes, as macrophage precursors, may hinder immunological host defense mechanisms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7328934     DOI: 10.1007/bf02469025

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  14 in total

1.  Counts and characteristics of macrophage precursors in human peripheral blood.

Authors:  G Krikorian; W H Marshall; S Simmons; F Stratton
Journal:  Cell Immunol       Date:  1975-09       Impact factor: 4.868

2.  MONOCYTOSIS: A CURRENT APPRAISAL.

Authors:  J E MALDONADO; D G HANLON
Journal:  Mayo Clin Proc       Date:  1965-03       Impact factor: 7.616

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

5.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.

Authors:  P A Ward; J L Berenberg
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

6.  Monocytosis in malignant disease.

Authors:  O Barrett
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

7.  Defective regulation of chemotaxis in cirrhosis.

Authors:  E C Maderazo; P A Ward; R Quintiliani
Journal:  J Lab Clin Med       Date:  1975-04

8.  Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal.

Authors:  R Snyderman; H F Seigler; L Meadows
Journal:  J Natl Cancer Inst       Date:  1977-01       Impact factor: 13.506

9.  A qualitative and quantitative study of monocytes in patients with malignant solid tumors.

Authors:  C R Kjeldsberg; G D Pay
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

10.  Chemotactic factor inactivator in normal human serum.

Authors:  J L Berenberg; P A Ward
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more
  1 in total

1.  Altered monocyte function in patients with benign breast disease.

Authors:  A M Al-Sumidaie; S J Leinster; S A Jenkins
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.